133053-76-6

Usage

Uses

Used in Pharmaceutical Industry:
3-METHYL-6-NITROINDOLE is used as a building block in the synthesis of various pharmaceuticals for its potential biological activities, such as anti-inflammatory and anti-cancer properties. It plays a crucial role in the development of new drugs for treating various diseases.
Used in Agrochemical Industry:
3-METHYL-6-NITROINDOLE is also used as a building block in the synthesis of various agrochemicals, contributing to the development of new compounds for agricultural applications.
Used in Medicinal Chemistry Research:
3-METHYL-6-NITROINDOLE is utilized as a key intermediate in the field of medicinal chemistry, enabling researchers to explore its potential applications in drug discovery and the development of novel therapeutic agents.
Used in Drug Development:
3-METHYL-6-NITROINDOLE is employed in the development of new drugs, leveraging its potential biological activities to create innovative treatments for various diseases, including cancer and inflammatory conditions.

Upstream product

• 83-34-1 3-Methylindole 
• 51516-96-2 3-nitrophenylhydrazine hydrochloride 
• 99-09-2 3-nitro-aniline 
• 578-54-1 ortho-ethylaniline 
• 6283-25-6 H₂NC₆H₃(Cl)NO₂ 
• 106-95-6 allyl bromide 
• 134271-93-5 1-(3-nitrophenyl)-2-propylidenehydrazine 
• 67-56-1 methanol 
• 4769-96-4 6-nitroindole 
• 134271-93-5 (E)-1-(3-nitrophenyl)-2-propylidenehydrazine 
• 20191-74-6 2-ethyl-5-nitroaniline 
• 133053-75-5 methyl N-(6-ethyl-3-nitrophenyl)-formimidate 

Relevant academic research and scientific papers

CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS

The invention is concerned with the compounds of formula (I) and formula (II): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of using the compounds of formula (I) and formula (II) as well as pharmaceutical compositions containing such compounds. The compounds are useful in treating diseases and conditions mediated by TEAD, such as cancer.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Iridium-catalyzed methylation of indoles and pyrroles using methanol as feedstock

Iridium-catalyzed methylation of indoles and pyrroles using methanol as the methylating agent was achieved. This transformation takes place via a borrowing hydrogen methodology under an air atmosphere, which constitutes a direct route to 3-methyl-indoles and methyl-pyrroles.

Regioselective hydroarylation reactions of C3 electrophilic N-acetylindoles activated by FeCl3: An entry to 3-(Hetero)arylindolines

A method for the direct and rare umpolung of the 3 position of indoles is reported. The activation of N-acetylindole with iron(III) chloride allows the C-H addition of aromatic and heteroaromatic substrates to the C2-C3 double bond of the indole nucleus to generate a quaternary center at C3 and leads regioselectively to 3-arylindolines. Optimization, scope (50 examples), practicability (gram scale, air atmosphere, room temperature), and mechanistic insights of this process are presented. Synthetic transformations of the indoline products into drug-like compounds are also described.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

One-pot N-alkylation/Heck approach to substituted indoles

Here, we report the palladium-catalyzed one-pot N-alkylation/Heck cyclization of anilines to substituted indoles employing Pd(OAc)2/XPhos. The scope and limitations of this methodology will be described.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Reaction of indole and alkylindoles with ceric ammonium nitrate on silica gel

Treatment of N-methylindole with CAN-on-SiO2 furnished 2,2-bis(N-methyl-3′-indolyl)-N-methylindoxyl, whereas that of skatole, N-methyl and N-ethyl skatoles produced the respective 2-nitroskatoles along with 6-nitroskatole and N-methyl-5-nitroskatole.